Agamree (Vamorolone) is the first drug for Duchenne Muscular Dystrophy (DMD) to receive full approval in the European Union. However, it has not yet been launched in China and is not included in China's medical insurance system. In 2025, the price trends of Agamree have sparked widespread discussion. The version of Agamree produced by the Swiss pharmaceutical company Santhera Pharmaceuticals is priced at approximately $5,435 per box.
What is the Latest Price of Agamree in 2025?
For numerous DMD patients and their families, the latest price of Agamree is undoubtedly one of their primary concerns.
Price
In 2025, the price of Agamree remains at a relatively high level. The version of Agamree manufactured by the Swiss pharmaceutical firm Santhera Pharmaceuticals is still sold at around $5,435 per box. The above price is for reference only. As the currently only approved therapeutic drug for DMD, Agamree's significant role in improving patients' quality of life and slowing down the progression of the disease is self-evident.
Patient Assistance Programs
Given the high price of Agamree, many patients and their families may face financial pressure. To alleviate this burden on patients, Santhera Pharmaceuticals and some charitable organizations have launched patient assistance programs. These programs aim to provide patients with support in the form of financial aid, drug donations, or coupons.
Purchasing Channels for Agamree
For patients and their families looking to purchase Agamree, understanding legal purchasing channels is also crucial. Since Agamree has not yet been launched in China, domestic patients may need to obtain the drug through overseas purchasing channels.
Regular Overseas Pharmacies
Choosing regular overseas pharmacies is a reliable way to purchase Agamree. These pharmacies typically possess legal business qualifications, sound supply chain systems, and professional pharmacist teams, ensuring the authenticity and quality of the drugs. Patients can obtain information about recommended overseas pharmacies by consulting relevant forums, or seeking advice from doctors or pharmacists.
Official Channel Applications
Some patients may meet the eligibility criteria for special assistance programs offered by Santhera Pharmaceuticals or its partners. These programs may include drug donations, coupons, or financial support. Patients can visit the official website of Santhera Pharmaceuticals or contact its customer service department to learn about the specific application process and required materials.
Storage Methods for Agamree
Proper storage methods are crucial for ensuring the efficacy and safety of Agamree. Since Agamree is in the dosage form of an oral suspension, its storage conditions are relatively specific.
Storage of Unopened Products
For unopened Agamree oral suspension, it should be stored upright at room temperature ranging from 20°C to 25°C. A temperature fluctuation range of 15°C to 30°C is permitted. Avoid exposing the drug to direct sunlight or high-temperature environments, as this may cause the drug to deteriorate or become ineffective.
Storage of Opened Products
Once the Agamree oral suspension is opened, its storage conditions will change. The bottle should be stored upright in a refrigerator at a temperature between 2°C and 8°C, and kept away from the freezer compartment. The opened Agamree oral suspension should be used up within 3 months to prevent drug degradation or contamination. If it is not used up within this period, it should be discarded and replaced with a new batch of the drug.
